| |
| |
|
| Insider
Information: |
Arkowitz David |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
417,314 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,214,630 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
417,314 |
|
|
| Total
Value |
$2,214,630 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -191.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Idenix Pharmaceuticals Inc |
IDIX |
Chief Financial Officer |
2004-07-27 |
8,000 |
2004-07-27 |
0 |
Premium* |
|
|
AMAG Pharmaceuticals Inc |
AMAG |
EVP, CFO, CBO |
2011-05-31 |
1,806 |
2007-12-03 |
0 |
Premium* |
|
|
F-star Therapeutics, Inc |
FSTX |
Director |
2023-03-08 |
0 |
2016-11-23 |
0 |
Premium* |
|
|
Flexion Therapeutics Inc |
FLXN |
Chief Financial Officer |
2021-05-10 |
220,719 |
2018-06-01 |
0 |
Premium* |
|
|
Kineta Ord Shs |
KA |
Director |
2020-12-22 |
4,347 |
2020-12-22 |
0 |
Premium* |
|
|
Seres Therapeutics, Inc. |
MCRB |
|
2024-02-16 |
182,442 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
50 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial OfficerOfficer |
• – – |
2021-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
% |
|
| AMAG |
AMAG Pharmaceuticals Inc |
CFO and Chief Business Officer |
• – – |
2007-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
1,056 |
0 |
- |
|
| AMAG |
AMAG Pharmaceuticals Inc |
EVP, CFO and CBO |
• – – |
2009-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
4,236 |
0 |
- |
|
| AMAG |
AMAG Pharmaceuticals Inc |
EVP, CFO and CBO |
• – – |
2010-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
1,228 |
0 |
- |
|
| AMAG |
AMAG Pharmaceuticals Inc |
EVP, CFO and CBO |
• – – |
2010-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
16,886 |
0 |
- |
|
| AMAG |
AMAG Pharmaceuticals Inc |
EVP, CFO and CBO |
• – – |
2010-08-05 |
4 |
AS |
$0.00 |
$0 |
D/D |
(15,750) |
1,136 |
0 |
- |
|
| AMAG |
AMAG Pharmaceuticals Inc |
EVP, Chief Financial Officer |
• – – |
2011-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
3,011 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
40,250 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
85,172 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,370 |
20,756 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,896 |
24,652 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,179 |
28,831 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,098 |
37,929 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2020-01-03 |
4 |
S |
$0.00 |
$0 |
D/D |
(3,095) |
88,481 |
0 |
% |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
31,000 |
119,481 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2020-07-16 |
4 |
A |
$0.00 |
$0 |
D/D |
38,750 |
157,121 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Chief Financial Officer |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
71,900 |
222,948 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
70,492 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
112,992 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
166,613 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,209 |
179,822 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,625 |
186,381 |
0 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-02-16 |
4 |
AS |
$1.08 |
$4,254 |
D/D |
(3,939) |
182,442 |
0 |
% |
|
| AMAG |
AMAG Pharmaceuticals Inc |
CFO and Chief Business Officer |
• – – |
2009-12-01 |
4 |
B |
$31.78 |
$5,466 |
D/D |
172 |
478 |
2.74 |
- |
|
| MCRB |
Seres Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-10-30 |
4 |
AS |
$1.35 |
$5,489 |
D/D |
(4,066) |
175,756 |
0 |
% |
|
50 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
